Non-infectious uveitis comprehends a heterogeneous group of intraocular inflammatory diseases that arise without a known infectious trigger.
The term uveitis refers to a group of inflammatory disorders affecting the uvea, the middle layer of the eye.
The first therapeutical option in uveitis is corticosteroids.
Tumor necrosis factor alpha (TNF-α) is a pleiotropic cytokine expressed in a wide variety of inflammatory conditions contributing
Interferon (IFN) was first described in 1957 by Isaacs and Lindenmann
Daclizumab is the humanized form of IgG1 monoclonal antibody directed against the 55 kDa alpha subunit of the IL-2 receptor
Interleukin-6 (IL-6) is a key cytokine featuring redundancy and pleiotropic activity
Noninfectious uveitis has a complex and multifactorial etiology that involves the breakdown of the blood-eye and bloodretinal barriers
Abatacept (Orencia, Bristol-Myers Squibb Company, Princeton NJ, USA) is a fusion protein composed of the Fc region
Rituximab (RTX) is a chimeric human-mice monoclonal antibody directed against the surface marker CD20 of pre-B lymphocytes
The rate of biologic therapies use in patients with non-infectious uveitis is rising rapidly
In the last decade, the use of biological therapy, mainly tumor necrosis factor (TNF) antagonists
This chapter is intended to provide a short glimpse on recent emerging therapies that could play an important role in the field